Radiologists can, with confidence, recommend a six-month follow-up diagnostic mammogram rather than an immediate biopsy for patients with “probably benign” breast lesions, a new study emphasizes.
The study found that six-month short-interval follow-up examinations had an 83% sensitivity, which is similar to the sensitivity of other diagnostic mammograms, said Erin J. Aiello Bowles, MPH, lead author of the study from the Group Health Center for Health Studies. High sensitivity means identifying a high proportion of “true positives” (actual cancer cases) and a low proportion of “false negatives” (cases mistakenly deemed benign).
The study included 45,007 initial short-interval follow-up mammograms. “Short-interval follow-up mammograms are done to monitor for changes in ‘probably benign’ breast lesions (findings seen on mammograms that have a very low probability of being cancer). Because the probability of cancer is so low, we don’t want to put the patient through an unnecessary biopsy, which is an invasive procedure that increases both patient anxiety and medical costs,” said Aiello Bowles. “At the same time, we want to closely monitor these patients, because changes in ‘probably benign’ lesions occasionally mean cancer, and we want to detect the cancers as early as possible,” she said. In the study, 360 women with “probably benign” lesions were diagnosed with breast cancer within six months; and 506 women were diagnosed with cancer within 12 months (altogether about one in 100 of the “probably benign” lesions), Aiello Bowles said.
“The Breast Imaging-Reporting and Data System (BI-RADS) recommends that women with a BI-RADS category 3 (probably benign) lesion get a six-month diagnostic mammogram, with follow-up continued for the next two to three years until long-term stability is demonstrated,” said Dr. Edward Sickles, a coauthor and radiologist involved in the study from the University of California San Francisco. “This study emphasizes that radiologists and patients need to follow that recommendation,” he said.
Source: American Roentgen Ray Society
Related stories:
Study links vitamin D to colon cancer survival
Patients diagnosed with colon cancer who had abundant vitamin D in their blood were less likely to die during a follow-up period than those who were deficient in the vitamin, according to a new study by scientists at Dana-Farber Cancer Institute.
Increased incidence of melanoma found in rheumatoid arthritis patients treated with methotrexate
A chronic, inflammatory disease of unknown origin, rheumatoid arthritis (RA) affects about 1 percent of adults worldwide. Marked by joint destruction, RA often leads to disability and diminished quality of life. It can also lead to an early death from cancer. Various studies have linked RA to an increased risk of Hodgkin's and non-Hodgkin's lymphoma, leukemia, myeloma, and lung cancer.
Biologic treatment for rheumatoid arthritis and the risk of cancer
The relationship between rheumatoid arthritis (RA), an autoimmune disease marked by chronic inflammation of the joints and tissue surrounding vital organs, and the incidence of cancer is complicated. Epidemiologic studies have generally demonstrated that blood, lung, and skin cancers are increased among RA patients, while breast and colon cancers are decreased.
Nanotweezers Unlock Anticancer Drug Secrets
The annoying bulges of an overwound telephone cord that shorten its reach and limit a caller’s motion help explain why drugs called camptothecins are so effective in killing cancer cells, according to investigators led by Mary-Ann Bjornsti, Ph.D., at St. Jude Children’s Research Hospital, and Nynke Dekker, Ph.D., at Delft Technology University.
Double-Duty Nanoparticles Overcome Drug Resistance in Tumors
Cancer cells, like bacteria, can develop resistance to drug therapy. In fact, research suggests strongly that multidrug resistant cancer cells that remain alive after chemotherapy are responsible for the reappearance of tumors and the poor prognosis for patients whose cancer recurs. Indeed, multidrug resistance occurs in over 50% of patients whose ovarian cancer relapses, accounting in large part for the high mortality associated with ovarian cancer.
Dendritic cells stimulate cancer-cell growth
Since their discovery at Rockefeller University some 30 years ago, dendritic cells have been recognized as key players on the immune-system team, presenting antigens to other immune cells to help them respond to novel insults. Now, Rockefeller scientists have shown that dendritic cells also have other, non-immune actions, and may in fact directly modify the biology of some types of cancer cells.
Scientists show hallucinogen in mushrooms creates universal 'mystical' experience
Using unusually rigorous scientific conditions and measures, Johns Hopkins researchers have shown that the active agent in "sacred mushrooms" can induce mystical/spiritual experiences descriptively identical to spontaneous ones people have reported for centuries.
Food scientists confirm commercial product effectively kills bacteria in vegetable washwater
Research conducted by food science faculty at the University of Idaho and Washington State University indicate that a commercially available fruit and vegetable wash, when used in a food-manufacturing setting, can dramatically decrease the number of disease-causing organisms in produce-processing washwater. That could reduce by manyfold the potential for cross-contamination within the water by such "gram-negative" bacteria as Salmonella and E. coli O157:H7.